Form 4: Bone Biologics Director Phillip Terry Meikle II Acquires Stock Options

Director Phillip Terry Meikle II acquired stock options in Bone Biologics Corp on October 16, 2024.

Summary

• Phillip Terry Meikle II, a director of Bone Biologics Corp, filed a Form 4 on October 18, 2024, reporting transactions related to the company's stock.
• On October 16, 2024, Meikle acquired non-employee stock options for 9 shares of common stock at an exercise price of $1.88, expiring on October 16, 2034.
• Additionally, Meikle acquired non-employee stock options for 28,185 shares of common stock at an exercise price of $1.88, expiring on October 16, 2034.
• The options for 28,185 shares vest in four equal installments on 12/17/24, 3/19/25, 6/19/25 and 9/17/25.
• These transactions were made under the Bone Biologics Corporation 2015 Equity Incentive Plan and are exempt under Rule 16b-3.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is a standard practice. There are no explicit positive or negative implications.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule for the larger option grant (28,185 shares) provides an incentive for continued service and performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. The size and vesting schedule of the grants are typical for companies of Bone Biologics' size and stage of development.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• Companies like Zimmer Biomet and Stryker, which are larger players in the orthopedics market, also utilize stock options as part of their executive compensation plans.
• The vesting schedules, typically over a period of 3-4 years, are designed to retain talent and incentivize long-term performance, aligning with industry norms.

Stakeholder Impact

• The stock option grants could potentially dilute existing shareholders if the options are exercised.
• The grants incentivize the director to work towards increasing shareholder value.

Key Dates

Keywords

stock options, Form 4, Bone Biologics Corp, BBLG, director, Phillip Terry Meikle II, equity incentive plan, beneficial ownership